Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Pressures Intensify In Asia As Healthcare Budget Battles Rage On

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Pharmacies and hospitals in the Philippines had until Tuesday to halve prices of a range of drugs or face the wrath of regulators keen to lower drug prices

You may also be interested in...



Taiwan May End Free HIV/AIDS Medication To Trim CDC Budget Shortfall

Taiwan may end a decade-long program of providing free AIDS drugs, citing rising costs as life expectancy grows.

Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec

SEOUL - Seoul's Administrative Court ruled in favor of Novartis and suspended the Korean health ministry's plan to cut the price of the Swiss-based company's leukemia drug Glivec (imatinib) by 14 percent beginning Sept. 15

China's Changing Drug Market In The Wake Of Essential Drugs List

SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain

Related Content

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel